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Summary The combination of irradiation and four agents of clinical interest in the treatment of cervix
carcinoma (bleomycin, etoposide, cisplatin and ifosfamide) have been investigated using two human cervix
carcinoma xenografts in nude mice. As a model of clinical brachytherapy regimes, radiation was administered
at a continuous low dose rate of 5cGymin-1 to a total dose of 9 or 12Gy. No substantial enhancement in
tumour growth delay over that observed for radiation alone was observed with bleomycin, etoposide or
cisplatin. Ifosfamide, however, led to substantial additional growth delay, an effect which was lost when
irradiation was administered at a higher dose rate of 70cGymin-1. As dose-rates of around 5cGymin-1
allow greater repair of radiation damage than at the higher dose-rate without significant cell cycling or
repopulation, it is possible that ifosfamide may act as an inhibitor of repair processes in this model. It would
be of interest to evaluate the role of ifosfamide and brachytherapy regimes in the clinical treatment of
carcinoma of the cervix.
Carcinoma of the uterine cervix is the third most frequently
occurring female gynaecological malignancy. Overall it
accounts for 6% of female malignancies. In England and
Wales the incidence is 4,400 new cases per year with an
overallsurvivalof57%(CancerResearchCampaign, 1986).With
160,000 deaths per year from all cancers this means that
carcinoma of the cervix accounts for 3% of cancer deaths.
Although chemotherapy for metastatic disease does not
achieve long-term survival the response rates are relatively
high. If chemotherapy were used in a more favourable
situation one might hope to improve outcome (Ward et al.,
1985). Thus chemotherapy is being tested in the adjuvant
setting along with either surgery or radiotherapy where one
of the problems of access of chemotherapy to post-irradiated
tissue is eliminated.
The present paper describes the interaction between com-
monly used chemotherapeutic agents (bleomycin, cisplatin,
etoposide and ifosfamide) and low dose-rate irradiation
(5cGymin-1) in two recently established carcinoma of the
cervix cell lines used in xenograft. These drugs have been
used extensively in clinical trials both singly and in combin-
ation (Blake et al., 1986; Cohen et al., 1978; Thigpen et al.
1979; Friedlander et al., 1983). We have chosen to use low
dose-rate irradiation at 5cGymin-i on the basis of in vitro
studies from this laboratory that have shown doses of 2-
5cGymin- 1 allow extensive recovery from radiation damage
without significant repopulation or cell cycle progression
(Steel et al., 1986). In the clinical setting brachytherapy to
the cervix is given at approximately 10Gy to 30Gy/24h
which is 0.7cGymin- 1 to 2cGymin-1. In these experiments
the low dose-rate of 5cGymin-1 enabled the exposure time
to be kept below four hours (total dose 12Gy), thus
minimising stress to the mice.
The aim was to evaluate chemotherapy induced improve-
ment in tumour growth delay in this experimental system
while monitoring any increased toxicity of such combined
modality treatment using body weight measurements and
mortality (Tannock, 1984, 1986).
Materials and methods
Xenografts
Two recently established carcinoma of the cervix cell lines
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HX155c and HX156c were used. The biological characteris-
tics of these cell lines and the xenograft lines, which were
established from initial pre-treatment biopsies taken from
patients presenting to The Royal Marsden Hospital, have
been described previously (Kelland et al., 1987, for the cell
lines; and Kelland & Tonkin, 1988, for the xenograft lines).
The tumour lines were passaged in female Nu/Nu mice
which were housed in negatively pressured plastic film
isolators and fed on standard animal chow and water.
Animals were removed from the isolator and put in a sterile
hood for transplantation. The mice were placed under ether
anaesthesia and ear-marked at this time. An incision was
made over the lumbar spine area and a 1-2mm tumour
nodule was implanted subcutaneously over the dorsal spine.
In order to keep the tumour in position a skin tuck was
made with a skin clip just posterior to the nodule and a
second clip was used to close the wound. The mice were
observed for 4 to 12 weeks when the clips were removed
from suitably positioned tumours of 6-9mm in diameter.
Chemotherapeutic agents
We used maximum tolerated doses of drug for nude mice
determined previously in the department or evaluated
immediately prior to these experiments. All drugs were
dissolved and dilutions made in PBS with 0.6ml as the
maximum volume of injection. All control mice were given
PBS as a single i.p. injection.
Etoposide vehicle was made up as a 2mgml-P solution of
polyethyleneglycol, tween 80, citric acid and absolute
alcohol. Cisplatin, etoposide and ifosfamide were all given
within 2h of the start of irradiation. Bleomycin was adminis-
tered 2 days prior to irradiation as preliminary 'time-line'
experiments showed this to be optimal for achieving maxi-
mum antitumour activity when combined with radiation.
Experiments were done using a control, drug only, irradia-
tion only and drug with irradiation arms where the control
and irradiation alone groups received a single i.p. injection
of PBS at the same time as the drug was given to the other
mice.
Drug doses were: bleomycin 150,ugg-1; cisplatin 5 ugg-1;
Etoposide 60 ugg-1; ifosfamide 120/9gg-.
Irradiation
For irradiation each mouse was put in an individual perspex
holder and placed behind lead shielding to protect normal
tissues. Low dose-rate experiments were performed at
5cGymin-I using a 60Co y-radiation source (100Ci). The
mice were positioned in a line of 5 per dose-rate tested. The
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maximum duration of experiment for low dose-rate irradia-
tion was 4h. A total dose of 9Gy irradiation at 5cGymin-1
was delivered from the 100Ci 60Co source for all experi-
ments except with etoposide where a total dose of 12Gy was
used at the same dose-rate. High dose-rate experiments were
done at 70cGymin I using a large 60Co y-radiation source
(2000Ci) and all these experiments were complete in
<20min.
Experimental endpoint and statistical analysis
Tumours were measured in two perpendicular diameters
using calipers and tumour weight was calculated from a
calibration curve. The weight of each mouse was docu-
mented at each measurement. The results are shown as
Relative Tumour Weight on a logarithmic scale plotted
against time in days after the day of irradiation. The graphs
represent mean values for 5 to 15 individual tumours and the
error bars for the Ifosfamide experiments indicate the
standard error of the mean (s.e.). The Specific Growth Delay
(SGD) values were calculated from
Specific Growth Delay (SGD)= 2-T
where T2 is the time to reach twice tumour weight in the
treated tumours in days and T1 is the time in days to reach
twice tumour weight in the control tumours. Dt the doubling
time of the control tumours in days.
Results
The results for HX155 with bleomycin and cisplatin are
shown in Figures la and lb and Table I. Cisplatin alone
(Figure lb) appeared to cause little tumour growth delay.
However, bleomycin alone (Figure la) resulted in a specific
growth delay (SGD) of 1.3. Irradiation alone gave a SGD of
3 to 3.5 in both experiments but the addition of either drug
did not appear to result in a significantly greater SGD than
that observed with radiation alone.
The results of HX156 with bleomycin and etoposide are
shown in Figure lc,d respectively and Table I. There was a
maximum SGD of 1.3 for bleomycin and irradiation but this
was not significantly different from the SGD for bleomycin
or irradiation alone and much less than the SGD noted for
HX155. As a consequence of these results the etoposide
experiments using HX156 (Figure ld) were performed with a
total dose of 12Gy radiation rather than 9Gy but there was
little obvious improvement in SGD when drug was combined
with irradiation than for irradiation alone.
In the experiments with low dose-rate irradiation and
ifosfamide there was substantial additional growth delay
with combined treatment (Figure 2a; Table II). The SGD for
irradiation was 2.3 and for combined irradiation and ifosfa-
mide the SGD was 10. There was only little tumour growth
delay for ifosfamide alone.
To further evaluate the effect of combined modality
treatment involving ifosfamide, the experiments were
repeated using 9Gy total dose irradiation given at a high
dose-rate of 70cGymin-1 on a 2000Ci 60Co source. The
result is shown in Figure 2b and Table II and demonstrated
that high dose-rate irradiation with ifosfamide gave similar
SGD as irradiation alone with values of 4-4.3. Toxicity
monitoring revealed no additional weight loss in mice when
combined treatment was given than with chemotherapy or
irradiation alone and no treatment related deaths were
observed.
Discussion
In combining radiotherapy and chemotherapy one aims to
improve the response rate achieved by either modality alone.
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Figure 1 Tumour growth delay for xenograft tumours in nude
mice with chemotherapy and/or irradiation.
la HX155; lb HX155; Ic HX156; Id HX156.
The difficulty is to achieve a higher response without
unacceptable toxicity, that is, to improve the therapeutic
ratio. Four mechanisms have been used to describe the ways
in which an improved therapeutic ratio could be achieved.
They are, spatial co-operation, independent cell kill, normal
tissue protection and enhancement of tumour response
(Steel, 1979).
In the experiments reported here several commonly used
chemotherapeutic agents have been used with low dose-rate
irradiation (etoposide, cisplatin, bleomycin and ifosfamide).
Only ifosfamide and irradiation resulted in a much greater
growth delay than irradiation alone. These experiments
demonstrated an additive response of low dose-rate irradia-
tion and ifosfamide giving a SGD of 10 with a SGD of 2.3
for irradiation alone in comparison to the high dose-rate740 K.S. TONKIN et al.
Table I Specific Growth Delay (SGD) for chemotherapy and low dose-rate irradiation
Control
tumour
Cell line doubling Treatment Irradiation and
designation time (days) Irradiationa chemotherapy chemotherapy
Bleomycin (150 gg1)
HX155 8 3.0 1.3 3.5
HX156 6 0.7 0.7 1.3
Cisplatin (5 ugg 1)
HX155 6.5 2.3 0.3 2.7
Etoposide (60pgg 1)
HX156 15 1.3 0.3 1.3
aIrradiation was 9Gy total dose except HX156, etoposide when 12Gy total dose was
administered.
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Figure 2 Tumour growth delay of HX155 xenograft tumours in
nude mice with Ifosfamide and irradiation. Low dose-rate
(5cGymin-1) irradiation: (a) and high dose-rate (70cGymin-1)
irradiation; (b) Control (0) Ifosfamide (0) Irradiation (U)
Ifosfamide and irradiation (O).
irradiation experiments which resulted in an SGD of 4-4.3
for both irradiation and irradiation and ifosfamide.
Using the terminology of Steel this result is called
'enhancement'. This describes a positive interaction where
the dose response curve for only one modality is known. In
this instance only the dose response for irradiation has been
established in the nude mouse. The result of combined
treatment was marked tumour growth delay where either
modality alone did not achieve a substantial effect. When
ifosfamide was given with high dose-rate irradiation the
tumour growth delay achieved by the combination of drug
Table II Specific Growth Delay (SGD) for ifosfamide and irradia-
tion in HX155
Treatment Specific growth delay
Ifosfamide (120igg1) 0.9
Low dose-rate irradiation (5cGymin
9Gy total dose) 2.3
High dose-rate irradiation (70cGyminm
9Gy total dose) 4.0
Ifosfamide and low dose-rate irradiation 10.0
Ifosfamide and high dose-rate irradiation 4.3
Mean control (untreated) tumour doubling times were 7 days for
the low dose-rate experiments and 9 days for the high dose-rate
experiments.
and irradiation was no different to that achieved by irradia-
tion alone. In addition the growth delay for high dose-rate
irradiation, with or without Ifosfamide, was less than the
growth delay for the combination of low-dose rate irradia-
tion and drug by a factor of four. This suggests that the
mechanism by which ifosfamide acts with low dose-rate
irradiation, might involve inhibition of the repair that would
normally be seen with low dose-rate irradiation given alone.
The concept of the loss of low dose-rate sparing has been
reported from this laboratory previously when lung tolerance
was investigated using irradiation and cyclophosphamide
(Lockhart et al., 1986) and the potential for lung damage
when irradiation is combined with cyclophosphamide in
bone marrow transplantation is well documented (Barrett et
al., 1983).
As far as we are aware this is the first report of increased
tumour growth delay with chemotherapy and low dose-rate
irradiation in a human tumour model. More data, particu-
larly in vitro using tumour cell lines, are needed to evaluate
the mechanism of this interaction. Ifosfamide is an alkylating
agent which causes cell death largely as a result of its ability
to form cross-links in DNA, although it also acts by
substitution reactions, base alkylation and phosphate group
esterification. Radiation is known to cause base damage,
single and double stranded DNA breaks and DNA-DNA
and DNA-protein cross-links (Elkind, 1979 for a review). In
addition there is some recent evidence (Utsumi et al., 1988)
to suggest that, in S-phase cells, radiation-induced sublethal
damage may be a cross-linking lesion. It is possible that,
during continuous low dose-rate irradiation, ifosfamide
could be inhibiting the repair of such a lesion. Further study
is required to elucidate the mechanism for the striking
enhancement in observed tumour growth delay.
To date there has been a paucity of data to support the
use of radiotherapy and chemotherapy concurrently in solid
tumours as patient survival is rarely improved and greater
toxicity usually results (Tannock, 1984; 1986). However in
some squamous cell tumours such as carcinoma of the anal
canal there have been encouraging reports of improved local
control with combined treatment using 5-Fluorouracil (5-Fu)
(Cummings et al., 1984; Meeker et al., 1986).
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rate irradiation is used as intra-cavitary treatment in early
stage disease there is potential benefit, for those patients
with a high risk of recurrence, to use ifosfamide concurrently
with irradiation if normal tissue tolerance and systemic
toxicity are acceptable. Clinical testing is required to deter-
mine if this approach produces improved local and/or syste-
mic tumour control and/or survival.
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